A new tool in the field of in-vitro diagnosis of allergy: preliminary results in the comparison of ImmunoCAP© 250 with the ImmunoCAP© ISAC
Authors:
- 14 December 2010
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 49 (2) , 277-280
Abstract
Background: The ImmunoCAP© ISAC allows for the determination of specific immunoglobulin E (IgE) against 103 recombinant or purified allergen components in a single analytical step. The aim of our study was to perform a comparison of the specific IgE results measured with the microarray method to those obtained using the traditional method of ImmunoCAP©. Methods: We selected 86 clinically relevant patients on the basis of their specific IgE for recombinant allergens (ImmunoCAP© 250, Phadia). Also, we selected two patients with a high total IgE to evaluate the non-specific binding of IgE. All samples were screened with the ImmunoCAP© ISAC. Then, we compared the 555 specific IgE antibodies results provided by ImmunoCAP© ISAC with the specific IgE levels obtained with ImmunoCAP© 250. Results: We observed that 82 of the 384 results found to be positive with ImmunoCAP© were negative with ISAC© (concordance 78.65%). Of 171 negative results obtained with ImmunoCAP©, 11 were positive with ISAC© (concordance 93.57%). No non-specific binding was observed. Conclusions: Our results show that the ImmunoCAP© ISAC has good analytical performance when compared with the ImmunoCAP© 250 method. We did not observe any non-specific binding. However, better sensitivity for some clinically relevant allergen components, such as rPru p 3 is needed.Keywords
This publication has 8 references indexed in Scilit:
- Component‐resolved diagnosis from latex allergy by microarrayClinical & Experimental Allergy, 2010
- Systemic reactions to peach are associated with high levels of specific IgE to Pru p 3Allergy, 2009
- Quality Control and Protein MicroarraysClinical Chemistry, 2009
- From allergen structure to new forms of allergen-specific immunotherapyCurrent Opinion in Immunology, 2002
- Recombinant Marker Allergens: Diagnostic Gatekeepers for the Treatment of AllergyInternational Archives of Allergy and Immunology, 2002
- Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatmentThe FASEB Journal, 2002
- The recombinant allergen‐based concept of component‐resolved diagnostics and immunotherapy (CRD and CRIT)Clinical & Experimental Allergy, 1999
- Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases.Journal of Experimental Medicine, 1988